Back to homepage

Tag "biosimilars"

Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature

Authors: Luis Miguel Juárez-Salcedo MD, Diego Conde-Royo MD, Keina Quiroz-Cervantes MD, Samir Dalia MD

This article discusses the role of mAbs in follicular lymphoma and marginal zone lymphoma along with reviewing the current data about the use of biosimilar mAbs in these diseases.

More

Considerations for the US health-system pharmacist in a world of biosimilars

Authors: Andrea Zlatkus CRHC, Todd Bixby RPh, Kavitha Goyal MD

This editorial article provides an overview of the evolving healthcare landscape shaped by the entry of multiple biosimilars, including for a given reference product, and their impact on the healthsystem pharmacist with respect to formulary assessment, implementation, and education of various health-system stakeholders, including patients.

More

The biosimilars journey: current status and ongoing challenges

Authors: Igor Age Kos MD, Valderílio Feijó Azevedo MD, PhD, Daniel Egg Neto, Sérgio Cândido Kowalski MD, PhD

Biosimilar products are already approved and marketed in several countries. This review focuses on remaining challenges regarding biosimilars, such as the lack of regulatory harmony, especially concerning naming, the marketed intended copies, the interchangeability, and the biosimilars in orphan diseases.

More